|
DK1143917T3
(da)
*
|
1998-11-17 |
2004-06-01 |
Ortho Mcneil Pharm Inc |
Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
|
|
JP2004517029A
(ja)
*
|
1998-12-03 |
2004-06-10 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
精神分裂病の処置のためのトピラメート及び関連誘導体
|
|
AU763601B2
(en)
|
1999-02-08 |
2003-07-31 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating autism
|
|
ES2238999T3
(es)
|
1999-02-24 |
2005-09-16 |
University Of Cincinnati |
Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
|
|
MXPA01010217A
(es)
|
1999-04-08 |
2005-09-08 |
Johnson & Johnson |
Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos.
|
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
|
WO2000076493A1
(en)
|
1999-06-14 |
2000-12-21 |
Thomas Najarian |
Combination therapy for effecting weight loss and treating obesity
|
|
US20080103179A1
(en)
*
|
2006-10-27 |
2008-05-01 |
Tam Peter Y |
Combination Therapy
|
|
US7659256B2
(en)
*
|
1999-06-14 |
2010-02-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
|
US7553818B2
(en)
*
|
1999-06-14 |
2009-06-30 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
|
US20080255093A1
(en)
*
|
1999-06-14 |
2008-10-16 |
Tam Peter Y |
Compositions and methods for treating obesity and related disorders
|
|
US7674776B2
(en)
*
|
1999-06-14 |
2010-03-09 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
|
US6191117B1
(en)
*
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
|
AU2001280865A1
(en)
|
2000-08-02 |
2002-02-13 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of depression
|
|
WO2002043731A2
(en)
|
2000-11-30 |
2002-06-06 |
University Of Florida |
Treatments for neurogenetic disorders, impulse control disorders, and wound healing
|
|
US7041650B2
(en)
*
|
2001-07-09 |
2006-05-09 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivative salts
|
|
WO2003020289A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
|
|
US20040235957A1
(en)
*
|
2001-10-12 |
2004-11-25 |
David Bleakman |
Use of sulfonamide derivatives as pharmaceuticals compounds
|
|
US20050025791A1
(en)
*
|
2002-06-21 |
2005-02-03 |
Julius Remenar |
Pharmaceutical compositions with improved dissolution
|
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
|
US6559293B1
(en)
*
|
2002-02-15 |
2003-05-06 |
Transform Pharmaceuticals, Inc. |
Topiramate sodium trihydrate
|
|
US20090088443A1
(en)
*
|
2002-02-15 |
2009-04-02 |
Julius Remenar |
Novel crystalline forms of conazoles and methods of making and using the same
|
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
WO2003074474A2
(en)
*
|
2002-03-01 |
2003-09-12 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
|
NZ537543A
(en)
*
|
2002-07-29 |
2007-08-31 |
Alza Corp |
Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
|
|
US7196209B2
(en)
*
|
2002-10-31 |
2007-03-27 |
Ortho-Mcneil Pharmaceutical, Inc. |
Continuous process for the preparation of fructopyranose sulfamate derivatives
|
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
|
US20050070524A1
(en)
*
|
2003-06-06 |
2005-03-31 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
|
|
MXPA06007510A
(es)
*
|
2003-12-29 |
2009-06-10 |
Johnson & Johnson |
Composiciones de farmaco y formas de dosis novedosas de topiramato.
|
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
|
TW200612905A
(en)
*
|
2004-06-16 |
2006-05-01 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
|
PE20060500A1
(es)
*
|
2004-08-24 |
2006-07-13 |
Janssen Pharmaceutica Nv |
Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
|
|
BRPI0610864A2
(pt)
*
|
2005-05-20 |
2010-08-03 |
Janssen Pharmaceutica Nv |
processo para preparação de derivados de sulfamida
|
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
|
US8716231B2
(en)
*
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
|
AR058389A1
(es)
*
|
2005-12-19 |
2008-01-30 |
Janssen Pharmaceutica Nv |
Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
|
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
|
US8937096B2
(en)
*
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
|
US20070191450A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
|
|
US20070191474A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
|
|
US20070191449A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Smith-Swintosky Virginia L |
Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
|
|
JP2009537635A
(ja)
*
|
2006-05-19 |
2009-10-29 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
癲癇の処置のための共同−療法
|
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
|
EP2394643B1
(en)
|
2006-11-17 |
2015-09-02 |
Supernus Pharmaceuticals, Inc. |
Sustained-release formulations of topiramate
|
|
CN102114002B
(zh)
|
2006-12-04 |
2016-05-11 |
苏佩努斯制药公司 |
托吡酯的增强的立即释放制剂
|
|
US20090247616A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
|
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
|
US8580298B2
(en)
|
2008-06-09 |
2013-11-12 |
Vivus, Inc. |
Low dose topiramate/phentermine composition and methods of use thereof
|
|
US20090304789A1
(en)
|
2008-06-09 |
2009-12-10 |
Thomas Najarian |
Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
|
|
PE20110060A1
(es)
|
2008-06-23 |
2011-01-31 |
Janssen Pharmaceutica Nv |
Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
|
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
|
WO2020104837A1
(en)
|
2018-11-21 |
2020-05-28 |
Rosemont Pharmaceuticals Limited |
Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
|